144 related articles for article (PubMed ID: 7842821)
1. Antibacterial activity of cefepime in vitro.
Liu YC; Huang WK; Cheng DL
Chemotherapy; 1994; 40(6):384-90. PubMed ID: 7842821
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
3. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial activity of cefprozil in vitro.
Liu YC; Huang WK; Chen DL
Chemotherapy; 1995; 41(6):427-32. PubMed ID: 8529432
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of cefpodoxime in vitro.
Liu YC; Huang WK; Cheng DL
Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
[TBL] [Abstract][Full Text] [Related]
7. In-vitro antibacterial activity of cefepime: a multicentre study.
Duval J; Soussy CJ; Acar JF; Bergogne-Bérézin E; Cluzel R; Thabaut A; Courvalin P; Grès JJ; Rollin C
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():55-61. PubMed ID: 8150767
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
10. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
11. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
Bell JM; Turnidge JD;
Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
[TBL] [Abstract][Full Text] [Related]
12. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
13. [A comparative study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and ampicillin against clinical isolates].
Ergova R; K'oleian E; Kharalambieva Ia; Mitov I; Docheva Iu
Vutr Boles; 2000; 32(1):13-7. PubMed ID: 11195191
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
Sultan T; Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the in-vitro activity of cefepime and other cephalosporins.
Lim VK; Halijah MY
Malays J Pathol; 1993 Jun; 15(1):65-8. PubMed ID: 8277793
[TBL] [Abstract][Full Text] [Related]
17. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin.
Qadri SM; Ueno Y; Saldin H; Cunha BA
Chemotherapy; 1993; 39(2):112-9. PubMed ID: 8458243
[TBL] [Abstract][Full Text] [Related]
19. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):1-21. PubMed ID: 11977919
[TBL] [Abstract][Full Text] [Related]
20. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
